SCHEMBL21456835

SCHEMBL21456835

O=c1[nH]nc(-c2ccccc2Cl)[nH]1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BTK Q06187 7/20 0.55
DCUN1D1 Q96GG9 2/20 0.50
NOTUM Q6P988 1/20 0.50
GUSB P08236 1/20 0.50
NPC1 O15118 2/20 0.49
RAB9A P51151 2/20 0.49
ALPL P05186 2/20 0.49
TP53 P04637 1/20 0.49
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2D6 P10635 1/20 0.49
CYP2C9 P11712 1/20 0.49
HPGD P15428 1/20 0.49
CYP2C19 P33261 1/20 0.49
NR1H2 P55055 1/20 0.49
NR1H3 Q13133 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
KDM4E B2RXH2 2/20 0.47
ALDH1A1 P00352 2/20 0.47
GPR55 Q9Y2T6 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8291063 0.77 BTK (0.55) BTKDCUN1D1NOTUMNPC1RAB9A
SCHEMBL6748168 0.77 BTK (0.55) BTKDCUN1D1GUSBNPC1RAB9A
SCHEMBL20265414 0.75 PIM1 (0.41) BTKGUSBCYP3A4CYP2C9CYP2C19
SCHEMBL10671205 0.73 NOTUM (0.54) BTKNOTUM
SCHEMBL4784523 0.71 BTK (1.00) BTKDCUN1D1NPC1RAB9ACYP1A2
SCHEMBL31546406 0.70 FTO (0.49) DCUN1D1NOTUMGUSBNPC1RAB9A
SCHEMBL10944351 0.69 NR1H2 (0.77) DCUN1D1NOTUMGUSBNPC1RAB9A
SCHEMBL5914302 0.68 BTK (0.64) BTKDCUN1D1NOTUMGUSBALPL
SCHEMBL7598605 0.68 NOTUM (0.50) NOTUMGUSBCYP2D6HPGDTSHR
SCHEMBL11627267 0.68 CYP1A2 (0.56) DCUN1D1NOTUMNPC1RAB9AALPL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3553052-A1 5-OXO-4,5-DIHYDRO-1H-1,2,4-TRIAZOL DERIVATIVES FOR THE TREATMENT OF CANCER Bayer AG (DE) 2019-10-16 EP disclosed
EP-3553052-A1 5-OXO-4,5-DIHYDRO-1H-1,2,4-TRIAZOL DERIVATIVES FOR THE TREATMENT OF CANCER Bayer AG (DE) 2019-10-16 EP disclosed